SAN DIEGO, Nov. 9, 2015 /PRNewswire/ -- Mast
Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage
biopharmaceutical company leveraging its molecular adhesion and
sealant technology (MAST) platform to develop novel therapies for
sickle cell disease, heart failure, and stroke, today announced
that Peter Greenleaf has been
appointed to the Company's Board of Directors, effective
immediately.
Mr. Greenleaf brings to Mast Therapeutics' Board of Directors
over 20 years of experience in the biopharmaceutical industry,
including a track record of effective leadership through periods of
significant growth and extensive global commercial operations,
strategic planning, and product development expertise.
"We are thrilled to have Peter join our Board and we believe his
expertise helping small and mid-size companies transition into
industry leaders will be key as we approach the completion of our
Phase 3 study and position toward product commercialization,"
stated Brian M. Culley, Chief
Executive Officer. "Peter's extensive strategic, commercial,
capital markets, and transactional experience as well as his
demonstrated success in leadership and management across multiple
functional areas will be invaluable at this stage of our
development."
"I am happy to join Mast's Board of Directors at this critical
time in the Company's growth," said Mr. Greenleaf. "The
Company has made excellent progress moving its product candidates
forward and I look forward to working with the management team and
the Board of Directors to further Mast's efforts to make new
therapeutic options available for patients suffering from serious
and life-threatening diseases."
Mr. Greenleaf currently serves as Chief Executive Officer and
member of the Board of Directors of Sucampo Pharmaceuticals, Inc.
(NASDAQ: SCMP), which is focused on the development and
commercialization of medicines to meet major unmet medical needs of
patients worldwide. Prior to joining Sucampo, Mr. Greenleaf
served as Chief Executive Officer and member of the Board of
Directors of Histogenics Corporation, a regenerative medicine
company. Prior to Histogenics, Mr. Greenleaf was employed by
MedImmune LLC, the global biologics arm of AstraZeneca from 2006 to
2013, where he most recently served as President and where he was
instrumental in the sale of MedImmune to AstraZeneca for
approximately $15.6 billion in 2007.
While at MedImmune, Mr. Greenleaf drove the expansion of
MedImmune's pipeline into over 120 clinical and pre-clinical
programs and the commercialization of its marketed products. Mr.
Greenleaf also served as President of MedImmune Ventures, a wholly
owned venture capital fund within the AstraZeneca Group.
Prior to serving as President of MedImmune, Mr. Greenleaf was
the Chief Commercial Officer of the company, responsible for its
commercial, corporate development and strategy functions. Mr.
Greenleaf has also held senior commercial roles at Centocor
Biotech, Inc. (now Jansen Biotechnology, Johnson & Johnson) and
Boehringer Mannheim G.m.b.H. (now Roche Holdings). Mr.
Greenleaf currently chairs the Maryland Venture Fund Authority,
whose vision is to oversee implementation of InvestMaryland, a
public-private partnership to spur venture capital investment in
the state. Mr. Greenleaf is also a member of the Board of Directors
of the Biotechnology Industry Organization (BIO), where he serves
on the Governing Boards of the Emerging Companies and Health
Sections. Mr. Greenleaf earned a M.B.A degree from St. Joseph's
University and a B.S. degree from Western
Connecticut State University.
About Mast Therapeutics
Mast Therapeutics, Inc. is a
publicly traded biopharmaceutical company headquartered in
San Diego, California. The
Company is leveraging its MAST platform, derived from over two
decades of clinical, nonclinical and manufacturing experience with
purified and non-purified poloxamers, to develop vepoloxamer (also
known as MST-188), its lead product candidate, for serious or
life-threatening diseases and conditions typically characterized by
impaired microvascular blood flow and damaged cell membranes. The
Company is also developing AIR001, a sodium nitrite solution for
inhalation via nebulizer, for the treatment of heart failure with
preserved ejection fraction (HFpEF).
Vepoloxamer is an investigational new drug being tested in a
pivotal Phase 3 study called EPIC for the treatment of
vaso-occlusive crisis in patients with sickle cell disease and in a
Phase 2 study for the treatment of patients with chronic heart
failure. AIR001 is an investigational new drug being tested
in two institution-sponsored Phase 2a studies in patients with
HFpEF. More information can be found on the Company's web site at
www.masttherapeutics.com. (Twitter: @MastThera)
Mast Therapeutics™ and the corporate logo are trademarks of Mast
Therapeutics, Inc.
Forward Looking Statements
Mast Therapeutics cautions
you that statements included in this press release that are not a
description of historical facts are forward-looking statements that
are based on the Company's current expectations and assumptions.
Such forward-looking statements may include, but are not limited
to, statements relating to prospects for successful development and
commercialization of, the Company's investigational drugs,
vepoloxamer and AIR001, and anticipated timing of achievement of
development milestones, such as commencement and completion of
clinical studies or regulatory activities, and of announcement of
study data. Among the factors that could cause or contribute
to material differences between the Company's actual results and
the expectations indicated by the forward-looking statements are
risks and uncertainties that include, but are not limited to: the
uncertainty of outcomes in ongoing and future studies of the
Company's product candidates and the risk that its product
candidates, including vepoloxamer, may not demonstrate adequate
safety, efficacy or tolerability in one or more such studies,
including EPIC and the Phase 2 study of vepoloxamer in chronic
heart failure; delays in the commencement or completion of clinical
studies, including as a result of difficulties in obtaining
regulatory agency agreement on clinical development plans or
clinical study design, opening trial sites, enrolling study
subjects, manufacturing sufficient quantities of clinical trial
material, being subject to a "clinical hold," and/or suspension or
termination of a clinical study, including due to patient safety
concerns or lack of funding; the risk that, even if planned
clinical studies are successful, the FDA or other regulatory
agencies may determine they are not sufficient to support a new
drug application; the potential that, even if clinical studies of a
product candidate in one indication are successful, clinical
studies in another indication may not be successful; the potential
for additional nonclinical or clinical studies to be required prior
to initiation of a planned clinical study; the Company's reliance
on contract research organizations (CROs), contract manufacturing
organizations (CMOs), and other third parties to assist in the
conduct of important aspects of development of its product
candidates, including clinical studies, manufacturing, and
regulatory activities for its product candidates, and that such
third parties may fail to perform as expected; the risk that the
Company may be required to repay its outstanding debt obligations
at a time that could be detrimental to its financial condition,
operations and/or business strategy; the Company's ability to
obtain additional funding on a timely basis or on acceptable terms,
or at all; the potential for the Company to delay, reduce or
discontinue current and/or planned development activities,
including clinical studies, partner its product candidates at
inopportune times or pursue less expensive but higher-risk and/or
lower return development paths if it is unable to raise sufficient
additional capital as needed; the risk that, even if the Company
successfully develops a product candidate in one or more
indications, it may not realize commercial success and may never
achieve profitability; the risk that the Company is not able to
adequately protect its intellectual property rights, through
patents or otherwise, and prevent competitors from duplicating or
developing equivalent versions of its product candidates or that
the use or manufacture of its products or product candidates
infringe the proprietary rights of others; and other risks and
uncertainties more fully described in the Company's press releases
and periodic filings with the Securities and Exchange Commission.
The Company's public filings with the Securities and Exchange
Commission are available at www.sec.gov.
You are cautioned not to place undue reliance on forward-looking
statements, which speak only as of the date when made. Mast
Therapeutics does not intend to revise or update any
forward-looking statement set forth in this press release to
reflect events or circumstances arising after the date hereof,
except as may be required by law.
Logo -
http://photos.prnewswire.com/prnh/20120612/LA22456LOGO-a
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/mast-therapeutics-announces-appointment-of-peter-greenleaf-to-board-of-directors-300174638.html
SOURCE Mast Therapeutics, Inc.